Immune cells and bladder urothelium

The term Immune cells and bladder urothelium refers to the physiological and pathological interface between the specialized epithelial lining of the urinary bladder (urothelium) and the resident or recruited immune cell populations, such as T-cells, macrophages, and neutrophils. This is not a single molecular target but rather a complex cellular microenvironment that is central to the pathogenesis and treatment of urological diseases, most notably urothelial carcinoma and interstitial cystitis (Source: Nature Reviews Urology, 2017). In bladder cancer, the urothelium often expresses Programmed death-ligand 1 (PD-L1), which interacts with Programmed cell death protein 1 (PD-1) on T-cells to suppress the local immune response and allow tumor evasion (Source: NIH/NCI). Therapeutic interventions like intravesical Bacillus Calmette-Guérin (BCG) therapy function by triggering a robust, non-specific immune activation within this environment to eliminate malignant cells (Source: StatPearls, 2023). Additionally, the crosstalk between the urothelial barrier and immune cells is a key factor in chronic inflammatory conditions, where barrier dysfunction can lead to persistent immune activation and pain (Source: PubMed, 2021). Understanding this interface is essential for the development of targeted immunotherapies and the identification of biomarkers that predict patient response to treatment.

Other names

Bladder tumor microenvironmentUrothelial-immune interfaceBladder mucosal immune systemUrothelial immune microenvironment

Therapeutic agents targeting this cellular environment typically work by modulating the immune response within the bladder. Intravesical BCG induces a localized inflammatory response that recruits neutrophils and macrophages to the urothelium, while immune checkpoint inhibitors block the PD-1/PD-L1 pathway to reactivate T-cell mediated destruction of malignant urothelial cells.